•
Dec 31, 2023

Atai Q4 2023 Earnings Report

Atai Life Sciences reported financial results for Q4 2023, including a net loss attributable to shareholders of $18.3 million and R&D expenses of $14.2 million.

Key Takeaways

Atai Life Sciences reported Q4 2023 financial results, highlighting a net loss of $18.3 million and R&D expenses of $14.2 million. The company is focused on developing psychedelic-based therapies for mental health disorders and anticipates several clinical milestones in the coming year.

Strategic investment made in Beckley Psytech to advance psychedelic-based therapies.

Phase 2a open-label results for BPL-003 (intranasal 5-MeO-DMT) showed rapid and durable antidepressant effects.

Dosing commenced in Phase 1b study for VLS-01 (oral transmucosal DMT) with an optimized formulation.

Cash, marketable securities, and committed term loan funding are expected to fund operations into 2026.

Total Revenue
$18K
Previous year: $38K
-52.6%
EPS
-$0.12
Previous year: -$0.28
-57.1%
Gross Profit
-$83K
Previous year: -$15K
+453.3%
Cash and Equivalents
$45M
Previous year: $191M
-76.4%
Free Cash Flow
-$22M
Previous year: -$30.6M
-28.3%
Total Assets
$293M
Previous year: $305M
-3.9%

Atai

Atai

Atai Revenue by Segment

Forward Guidance

Atai anticipates several important milestones throughout the next year, including the Phase 2b readout from BPL-003.

Positive Outlook

  • Top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024
  • Data from a Phase 2a open-label study in Alcohol Use Disorder patients is expected mid-2024.
  • Initial results from the ELE-01 Phase 1/2a study are anticipated in H1 2024.
  • Pivotal Trial 1 (COMP005) top-line data is expected in the fourth quarter of 2024
  • A Phase 1/2a study of IBX-210 for the treatment of OUD is anticipated to initiate in the second half of this year.

Challenges Ahead

  • High degree of inter-individual PK variability and significant QT prolongation were noted across all doses for IBX-210
  • Both factors have the potential to increase site burden and limit scalability.
  • The ongoing Phase 2b study will evaluate 20mg and 40mg of RL-007 vs. placebo in patients living with CIAS. Topline results are expected mid-2025.
  • Pivotal Trial 2 (COMP006) top-line data is anticipated mid-2025.
  • Phase 2 open-label efficacy data in PTSD is expected in Spring 2024.